CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

Their core work

CHU Montpellier is one of France's major university hospitals, combining clinical care with translational research across multiple medical specialties. Their H2020 portfolio reveals deep involvement in clinical trials, regenerative medicine, diabetes management, and diagnostic innovation — consistently bridging laboratory science with patient-facing outcomes. They contribute clinical expertise, patient cohorts, and real-world validation to European research consortia, particularly in areas where hospital-based infrastructure is essential for moving therapies from bench to bedside.

What they specialise in

How they've shifted over time

In the earlier period (2015–2018), CHU Montpellier focused on cell-based regenerative therapies (ADIPOA2, RESPINE), cancer liquid biopsies (ELBA), and vaccine surveillance — a broad clinical research profile. From 2019 onward, a clear shift emerged toward data-driven and digital clinical approaches: diabetes data harmonization, digital mobility outcomes, automated diagnostics, and multi-omics biomarker integration. The trajectory suggests a hospital moving from traditional clinical trial participation toward digitally-enabled precision medicine and real-world evidence generation.

CHU Montpellier is increasingly investing in digital clinical outcomes, data harmonization, and technology-integrated disease management — making them a strong partner for projects requiring real-world clinical validation of digital health tools.

How they like to work

Overwhelmingly a participant (11 of 12 projects), with only one coordinator role (RESPINE), indicating they prefer to contribute clinical expertise within larger consortia rather than lead them. With 178 unique partners across 26 countries, they operate as an experienced, well-connected contributor comfortable in large international teams. Their single coordination of a phase 2b clinical trial (RESPINE) shows they can lead when the project aligns closely with their in-house clinical capabilities.

Extensive European network spanning 178 unique partners across 26 countries, reflecting broad participation in large multi-site clinical consortia. Their geographic reach covers most of the EU, with no apparent concentration beyond their French base.

What sets them apart

As a major French university hospital, CHU Montpellier offers something most research institutes cannot: direct access to patient populations, clinical trial infrastructure, and regulatory experience for human studies. Their combination of regenerative medicine expertise (MSC therapies), diabetes technology validation, and digital outcome measurement makes them particularly valuable for projects that need to prove a medical innovation works in real patients. Few partners can simultaneously provide laboratory capabilities, clinical cohorts, and hospital-grade data infrastructure.

Highlights from their portfolio

• RESPINE
  Their only coordinated project and largest budget (EUR 933K) — a phase 2b clinical trial of MSC injection for degenerative disc disease, demonstrating capacity to lead complex multi-site clinical studies.
• FORGETDIABETES
  Ambitious bionic pancreas project combining nano-sensing glucose monitoring with intraperitoneal insulin delivery and AI-driven control algorithms — at the frontier of diabetes technology.
• MOBILISE-D
  Large-scale effort to validate digital mobility assessment as a clinical endpoint across multiple conditions (COPD, Parkinson's, MS, ageing), positioning the hospital in the growing field of digital biomarkers.